1. Sinclair A, Morley JE, Rodriguez-Manas L, Paolisso G, Bayer T, Zeyfang A, Bourdel-Marchasson I, Vischer U, Woo J, Chapman I, Dunning T, Meneilly G, Rodriguez-Saldana J, Gutierrez Robledo LM, Cukierman-Yaffe T, Gadsby R, Schernthaner G, Lorig K. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502.
Article PubMed
2. Van Buren PN, Toto R. Current update in the management of diabetic nephropathy. Curr Diabetes Rev 2013;9:62-77.
Article PubMed
3. Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol 2013;58:259-271.
Article PubMed
4. Tramonti G, Kanwar YS. Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy. Endocrine 2013;43:494-503.
Article PubMed
5. Fagerudd J, Forsblom C, Pettersson-Fernholm K, Groop PH. FinnDiane Study Group. Implementation of guidelines for the prevention of diabetic nephropathy. Diabetes Care 2004;27:803-804.
Article
6. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R;. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013;98:1845-1859.
Article
7. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12:153-175.
Article PubMed
8. Green JB. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med 2012;124:54-61.
Article
9. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012;14:1032-1039.
Article PubMed
10. Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-28.
Article PubMed PMC
11. Lamberts H, Wood M, Hofmans-Okkes I. The International classification of primary care in the European community: with a multi-language layer. Oxford: Oxford University Press; 1993.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
Article PubMed
13. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991;29:452-472.
Article PubMed
14. The Anatomical Therapeutic Chemical Classification System [Internet]. Oslo: World Health Organization; 1991. cited 2014 Nov 21. 1990 - Available from:
http://www.who.int/.
15. Sicras Mainar A, Roldan Suarez C, Font Ramos B, Navarro Artieda R, Ibanez Nolla J. Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. Rev Clin Esp 2013;213:377-384.
Article PubMed
16. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed. BMJ 2000;320:1197-1200.
Article PubMed PMC
17. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109.
Article PubMed
18. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011;65:314-322.
Article PubMed
19. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87.
Article PubMed PMC
20. Jermendy G, Wittmann I, Nagy L, Kiss Z, Rokszin G, Abonyi-Toth Z, Katona L, Paragh G, Karadi I, Merkely B. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit 2012;18:CR72-CR77.
Article PubMed PMC
21. Erlich DR, Slawson DC, Shaughnessy A. Diabetes update: new drugs to manage type 2 diabetes. FP Essent 2013;408:20-24.
PubMed
22. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med 2013;125:7-20.
Article
23. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-1467.
Article PubMed
24. Guillausseau PJ. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol 2005;4:167-175.
Article PubMed
25. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101.
Article PubMed
26. Breitscheidel L, Stamenitis S, Dippel FW, Schoffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ 2010;13:8-15.
Article PubMed